000127124 001__ 127124
000127124 005__ 20240228140907.0
000127124 0247_ $$2doi$$a10.1158/1078-0432.CCR-14-1029
000127124 0247_ $$2pmid$$apmid:25351744
000127124 0247_ $$2ISSN$$a1078-0432
000127124 0247_ $$2ISSN$$a1557-3265
000127124 0247_ $$2altmetric$$aaltmetric:2820486
000127124 037__ $$aDKFZ-2017-03150
000127124 041__ $$aeng
000127124 082__ $$a610
000127124 1001_ $$0P:(DE-HGF)0$$aMerz, Maximilian$$b0$$eFirst author
000127124 245__ $$aDynamic contrast-enhanced magnetic resonance imaging for assessment of antiangiogenic treatment effects in multiple myeloma.
000127124 260__ $$aPhiladelphia, Pa. [u.a.]$$bAACR$$c2015
000127124 3367_ $$2DRIVER$$aarticle
000127124 3367_ $$2DataCite$$aOutput Types/Journal article
000127124 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522328397_8698
000127124 3367_ $$2BibTeX$$aARTICLE
000127124 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127124 3367_ $$00$$2EndNote$$aJournal Article
000127124 520__ $$aTo noninvasively assess bone marrow microcirculation before and after therapy in patients with newly diagnosed multiple myeloma with dynamic contrast-enhanced MRI (DCE-MRI).Ninety-six patients received DCE-MRI before and after primary treatment for newly diagnosed multiple myeloma. For the 91 evaluable patients, treatment consisted of high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) in 82 patients and chemotherapy without ASCT in 9 patients. In addition, 33 healthy volunteers were imaged as the control group. Analysis of DCE-MRI was performed according to the two-compartment model by Brix to quantify amplitude A (associated with blood volume) and exchange rate constant kep (reflecting vessel permeability and perfusion).Nonresponders showed significantly higher A-values before the start of therapy compared with responders (P = 0.02). In both responders and nonresponders to therapy, A-values dropped significantly (P = 0.004 and <0.001, respectively) after primary therapy, whereas lower values for kep were found only in responders (P < 0.001). Depth of remission was significantly correlated to decreased bone marrow microcirculation: Patients in near complete response (nCR) or complete remission (CR) after treatment showed significantly lower values for A compared with patients not achieving nCR+CR. The application of HDT or novel agents had no significant effect on DCE-MRI parameters after therapy, although patients treated with novel agents more often achieved nCR+CR (42%/12.5%; P < 0.002). Higher kep-values at second MRI were positively correlated to shorter overall survival (HR 3.53; 95% confidence intervals, 1.21-10.33; P = 0.02).Parameters from DCE-MRI are correlated to remission after primary therapy and outcome in newly diagnosed multiple myeloma.
000127124 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000127124 588__ $$aDataset connected to CrossRef, PubMed,
000127124 650_7 $$2NLM Chemicals$$aAngiogenesis Inhibitors
000127124 7001_ $$aRitsch, Judith$$b1
000127124 7001_ $$0P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aKunz, Christina$$b2$$udkfz
000127124 7001_ $$aWagner, Barbara$$b3
000127124 7001_ $$aSauer, Sandra$$b4
000127124 7001_ $$aHose, Dirk$$b5
000127124 7001_ $$aMoehler, Thomas$$b6
000127124 7001_ $$0P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDelorme, Stefan$$b7$$udkfz
000127124 7001_ $$aGoldschmidt, Hartmut$$b8
000127124 7001_ $$aZechmann, Christian$$b9
000127124 7001_ $$0P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aHillengass, Jens$$b10$$eLast author$$udkfz
000127124 773__ $$0PERI:(DE-600)2036787-9$$a10.1158/1078-0432.CCR-14-1029$$gVol. 21, no. 1, p. 106 - 112$$n1$$p106 - 112$$tClinical cancer research$$v21$$x1557-3265$$y2015
000127124 909CO $$ooai:inrepo02.dkfz.de:127124$$pVDB
000127124 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000127124 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000127124 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000127124 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000127124 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000127124 9141_ $$y2015
000127124 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CANCER RES : 2015
000127124 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127124 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127124 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127124 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127124 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000127124 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127124 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127124 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000127124 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000127124 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN CANCER RES : 2015
000127124 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x0
000127124 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000127124 980__ $$ajournal
000127124 980__ $$aVDB
000127124 980__ $$aI:(DE-He78)E010-20160331
000127124 980__ $$aI:(DE-He78)C060-20160331
000127124 980__ $$aUNRESTRICTED